Bleeding recurrence in patients with gastrointestinal vascular malformation after thalidomide
| Autor: | Hai-Ying Chen, Han-Bing Xue, Nan Feng, Jing-Yuan Fang, Sengwang Fu, Jun Dai, Yao Zhang, Zhi-Zheng Ge, Yun-Jie Gao, Xiao-Bo Li, Yun-jia Zhao, Huimin Chen |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
Adult
Male medicine.medical_specialty response rate Blood transfusion Vascular Malformations medicine.medical_treatment Angiogenesis Inhibitors Hemoglobin levels Gastroenterology Diagnostic Accuracy Study recurrence rate 03 medical and health sciences 0302 clinical medicine Internal medicine gastrointestinal vascular malformation medicine Humans In patient Adverse effect Aged Retrospective Studies Response rate (survey) Aged 80 and over business.industry Vascular malformation Retrospective cohort study General Medicine Middle Aged medicine.disease Thalidomide Gastrointestinal Tract 030220 oncology & carcinogenesis adverse effects 030211 gastroenterology & hepatology Female business Gastrointestinal Hemorrhage medicine.drug Research Article |
| Zdroj: | Medicine |
| ISSN: | 1536-5964 |
| Popis: | Thalidomide may be used for the treatment of gastrointestinal vascular malformation (GIVM), but the long-term response and adverse effects are unknown. Aim to study the recurrence rate of GIVM bleeding after thalidomide treatment, the response to treatment, and the adverse effects. This was a retrospective study of 80 patients with GIVM treated with thalidomide between November 2003 and November 2013. Patients received a course of 100 mg/day of thalidomide for 4 months and were followed up for at least 1 year. The response rate during follow-up, the recurrence rate after the 1st course of treatment, and the rate of retreatment were assessed. Comorbidities, the need for blood transfusion, yearly bleeding episodes, hemoglobin levels, hospitalization after thalidomide treatment, and the rate of adverse effects were also examined. The overall response rate during follow-up was 79.5% (62/78). The recurrence rate was 21.0% after the 1st course of thalidomide. The response rate of retreatment was 100%. After thalidomide treatment, yearly blood transfusion amounts, yearly bleeding episodes, and yearly hospitalization numbers were significantly decreased, while hemoglobin levels were significantly increased (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|